Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy

Table 4

Patients with known RAS testing.

Patient	Primary therapy	RAS testing	Secondary therapy	SVR
1	OBV/PTV/r+DSV+RBV; 12 weeks	not detected	LDV/SOF+RBV; 12 weeks	NO
5	OBV/PTV/r+DSV; 4 weeks	not detected	LDV/SOF; 12 weeks	YES
7	OBV/PTV/r+DSV; 1 week	not detected	LDV/SOF; 12 weeks	YES
15	SOF+RBV; 24 weeks	not detected	SOF+DCV 12 weeks →SOF+RBV 12 weeks	YES
20	LDV/SOF; 8 weeks	not detected	GZR/EBR+RBV; 16 weeks	YES
23	ASV+DCV; 24 weeks	NS5A: L31V, Y93H; NS3: S122R, D168E	OBV/PTV/r+DSV+RBV; 12 weeks	NO
25	ASV+DCV; 24 weeks	NS5A - Y93Y/H	LDV/SOF+RBV; 24 weeks	YES
28	OBV/PTV/r+DSV+RBV; 4 weeks	not detected	LDV/SOF; 24 weeks	YES
29	OBV/PTV/r+DSV+RBV; 12 weeks	not detected	LDV/SOF; 24 weeks	YES
30	OBV/PTV/r+DSV+RBV; 12 weeks	NS3-170I	LDV/SOF; 24 weeks	YES
31	ASV+DCV; 24 weeks	NS5A: 31V, 93H	OBV/PTV/r+DSV+RBV; 12 weeks	YES

RAS: resistance associated substitution; OBV: ombitasvir; PTV: paritaprevir; DSV: dasabuvir; RBV: ribavirin; LDV: ledipasvir; SOF: sofosbuvir; ASV: asunaprevir; DCV: daclatasvir.